These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 426672)

  • 1. Hemiparkinsonism. A human model for studying dopaminergic supersensitivity.
    Trabucchi M; Albizzati MG; Frattola L; Scarlato G
    Arch Neurol; 1979 Apr; 36(4):246-8. PubMed ID: 426672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental and clinical studies on bromocriptine in the Parkinsonian syndrome.
    Goldstein M; Lieberman A; Battista AF; Lew JY; Matsumoto Y
    Acta Endocrinol Suppl (Copenh); 1978; 216():57-66. PubMed ID: 206089
    [No Abstract]   [Full Text] [Related]  

  • 3. Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs.
    Davis LE; Adair JC
    Mov Disord; 1999 May; 14(3):520-2. PubMed ID: 10348484
    [No Abstract]   [Full Text] [Related]  

  • 4. Hemiparkinsonism-hemiatrophy syndrome.
    Ayromlou H; Najmi S; Arami MA
    Arch Iran Med; 2011 Mar; 14(2):152-4. PubMed ID: 21361726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.
    Goldstein M; Lieberman A; Battista AF; Lew JY; Hata F
    Pharmacology; 1978; 16 Suppl 1():143-9. PubMed ID: 25445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current treatment of Parkinsonian syndrome].
    Lechner H; Bertha G; Ott E
    Med Welt; 1980 Oct; 31(40):1444-6. PubMed ID: 7464500
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of carbidopa-levodopa in a patient with hydrocephalus and frozen movement.
    Aggarwal S; Childers MK; Jimenez D
    Brain Inj; 1997 Nov; 11(11):831-6. PubMed ID: 9354260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
    Kamenetskiĭ VK
    Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958
    [No Abstract]   [Full Text] [Related]  

  • 9. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
    Roberts JW; Cora-Locatelli G; Bravi D; Amantea MA; Mouradian MM; Chase TN
    Neurology; 1993 Dec; 43(12):2685-8. PubMed ID: 8255478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
    Miyoshi Y; Zhang Z; Ovadia A; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
    Ann Neurol; 1997 Aug; 42(2):208-14. PubMed ID: 9266731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vascular parkinsonism].
    Zhuchenko TD; Veĭn AM; Golubev VL; Shtul'man DR; Shvareva IS
    Zh Nevrol Psikhiatr Im S S Korsakova; 1998; 98(4):62-5. PubMed ID: 9606903
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.
    Figà-Talamanca L; Gualandi C; Di Meo L; Di Battista G; Neri G; Lo Russo F
    Neurology; 1985 Feb; 35(2):258-61. PubMed ID: 3969217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon.
    Teychenné PF; Ziegler MG; Lake CR; Enna SJ
    Ann Neurol; 1982 Jan; 11(1):76-9. PubMed ID: 6120678
    [No Abstract]   [Full Text] [Related]  

  • 15. Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
    Kelm-Nelson CA; Brauer AF; Ciucci MR
    Behav Brain Res; 2016 Jul; 307():54-64. PubMed ID: 27025445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease: recent advances in therapy.
    Jankovic J
    South Med J; 1988 Aug; 81(8):1021-7. PubMed ID: 3043683
    [No Abstract]   [Full Text] [Related]  

  • 17. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
    Bitton V; Melamed E
    J Clin Psychiatry; 1984 Jan; 45(1):28-30. PubMed ID: 6141157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E; Hubener K; Fischer PA
    Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP; Rüther E
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.